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Summary It is generally believed that there is a direct correlation between asthma
control and a patient’s health-related quality of life (HRQL). Objective and
subjective measures of asthma control are used interchangeably. A retrospective
analysis from 8994 patients from 27 randomized, controlled clinical trials with
persistent asthma was conducted to determine the degree of association which
exists between objective (lung function) and subjective (symptoms, quality of life)
measures. Assessments were made via forced expiratory volume in 1-second (FEV1),
self-reported symptoms and the Asthma Quality of Life Questionnaire (AQLQ) overall
scores. Baseline percent predicted FEV1 was weakly correlated with baseline
symptom-free days (SFD) and baseline overall AQLQ scores (r¼ 0.11 and 0.09,
respectively; P o0.001). Changes in percent predicted FEV1 correlated weakly with
changes in SFD but was more strongly correlated with changes in overall AQLQ scores
(r¼ 0.26 and 0.38, respectively; P o0.001). Additionally, SFD at both baseline and
endpoint were moderately correlated with overall AQLQ scores at baseline and
endpoint (r¼ 0.36 and 0.44; P o0.001). This study suggests that the impact of
asthma on a patients’ HRQL is not fully accounted for by objective measures such as
lung function. Thus, HRQL data complements rather than duplicates results from
traditional, objective assessments of asthma control.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is major public health concern in the US,
accounting for an estimated 14.5 million lost
workdays for adults,1 14 million lost school days
for children1 and significant healthcare cost.2 In
addition to the public health impact of the disease,
uncontrolled asthma negatively impacts individual
patients and their families.
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Traditionally, the asthma severity and the ade-
quacy of the control have been assessed by
objective measures such as lung function tests,
rescue short acting beta2-agonist use, airway
hyperresponsiveness to external stimuli, and num-
ber of hospitalizations due to asthma. It has been
assumed that if these objective clinical measures
improve, then the patient’s symptoms and quality
of life must improve as well. However, this may not
necessarily be the case. Although objective clinical
measures provide valuable information about the
status of the disease, they may be unable to fully
assess whether patients feel better and can
function better (physically, socially, and emotion-
ally) in everyday life.3 For example, patients may
begin to show signs of clinical improvement based
on objective measures, however if the treatment is
inconvenient, has unwanted effects or clinical
improvement does not reach a critical threshold,
the patient might not feel better and/or might
remain unable to function better while performing
daily activities. On the other hand, patients may
feel better and begin to experience an improve-
ment in daily functioning, which may not be
captured by the traditional clinical objective
measures such as forced expiratory volume in 1-
second (FEV1) and hyperresponsiveness. Asthma
may affect health-related quality of life (HRQL) in
ways that objective clinical measures cannot
predict. Symptoms are very important to patients;
they are the most common reason people seek
healthcare. However they alone may not reflect
asthma severity. Symptoms may reflect the level of
disease control achieved by treatment and self-
management while directly affecting the HRQL of
patients.
Although there are many questions about the
relationship between objective and subjective
measures of asthma control, clinicians often use
these measures interchangeably. It is generally
believed that there is a strong direct correlation
between objective and subjective measures of
asthma control. The true nature of these correla-
tions in asthma is poorly understood, therefore, we
decided to perform several analyses to evaluate
the association between asthma symptoms, lung
function and HRQL in patients with persistent
asthma.
Methods
This was a retrospective analysis of 27 randomized,
double-blind, double-dummy, parallel group studies
which examined the effects of inhaled corticoster-
oids, long-acting beta agonists, combination in-
haled corticosteroids and long-acting beta agonists
in a single inhaler, leukotriene modifiers, and
placebo. Studies were selected from an internal
clinical trials database on the bases of containing
HRQL, lung function and symptom assessments at
baseline and week 12. In addition, all studies had to
be published in peer-reviewed journals. The details
of each of these studies have been previously
reported 4–23 and are summarized in Table 1. In
order to have consistency between all studies,
endpoint was defined as the value that occurred at
week 12 regardless of the length of the study. Data
from 12 to 85 year old adult and adolescent
subjects with a diagnosis of persistent asthma for
the previous 3 months, using the American Thoracic
Society (ATS) definition,24 requiring use of beta-
agonists and with no recent hospitalizations for
asthma were used to determine the correlation
between lung function, symptoms, and HRQL.
Outcome measures were assessed at baseline and
change over a 12-week period.
Pulmonary function measure
Lung function was measured by periodic in-clinic
spirometry, which met or exceeded the minimum
performance recommendations of the American
Thoracic Society.25 No beta-agonist use was per-
mitted in the prior 6 h. Percent of predicted values
for FEV1 were calculated using the reference values
of Crapo standards for ages 18 and older28 and
Polgar predicted normal values for ages 12–17.26,27
Symptoms measure
Patients were asked to record their symptom scores
(based on wheezing, chest tightness, and shortness
of breath), nighttime awakenings due to asthma,
and supplemental albuterol on their diary cards at
baseline and throughout the study. A symptom-free
day (SFD) was defined as a day without asthma
symptoms as reported in the subject’s diary card
(score of 0). A rescue-free day (RFD) was defined as
a day where the number of puffs of albuterol for
the relief of asthma symptoms was reported as zero
on the diary card.
Health-related quality of life measure
The Asthma Quality of Life Questionnaire (AQLQ),28
an instrument designed to measure the functional
impairments that are most troublesome to asthma
patients was used, on treatment day 1 and
following 12 weeks of treatment or at the study
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discontinuation visit, to measure the changes in
HRQL. The AQLQ is a self-administered instrument
that has been shown to be valid, reliable and
responsive to change in HRQL.29–31 The AQLQ
contains 32-items in 4 domains that assess the
effect of drug treatment on activity limitations,
symptoms, emotional function, and exposure to
environmental stimuli. Patients recall their experi-
ences of the previous 2 weeks. For the activity
limitation domain, each patient selects 5 activities,
from a list of 26, which are expected to remain
important to them throughout the study. The other
3 domains have standard responses rated on a 7-
point scale, with lower scores indicating greater
impairment in asthma-related quality of life.
Statistical analysis
Data from 27 clinical studies with HRQL, lung
function, and symptom assessments were combined
for these retrospective analyses. Demographic and
baseline characteristics were summarized by study
and overall. Since the distribution of each of the
assessments appeared to be symmetric and not
markedly skewed, Pearson correlation coefficients
and Pearson partial correlation coefficients were
calculated to assess the relationships among per-
cent predicted FEV1, overall AQLQ score, and
patient-reported diary measures (percent SFDs,
percent RFDs, and albuterol use) at baseline and
at endpoint via change from baseline.
The baseline values for each patient for percent
predicted FEV1 and overall AQLQ score were
defined as the measurement obtained immediately
prior to randomization and endpoint values were
defined as the measurement obtained following 12
weeks of treatment or at the study discontinuation
visit, if prior to 12 weeks. Baseline for each
patient-reported diary measure was obtained by
calculating the mean of the measurements re-
corded on the 7 days preceding randomization and
endpoint was calculated as the mean of the last
week of measurements obtained prior to 12 weeks
or the study discontinuation visit. The final week
had to have at least 3 measurements to be included
in these analyses. Linear regression equations were
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Table 1 Description of studies.
Study n Age (yr) Male (%) White(%) Asthma duration (%) % Predicted FEV1 Steroid use (%)
p15 years 415 years No Yes
Total 8992 36.5 46.4 85.4 44.1 55.9 65.6 44.1 55.9
FLTA20044 271 36.4 53.9 90.8 42.8 57.2 66.5 0 100
FLTA20055 253 37.1 56.1 93.7 42.7 57.3 66.4 60.0 49.0
FLTA40016 304 37.6 54.9 91.8 35.9 64.1 65.3 0 100
FLTA40027 291 35.5 48.8 90.7 50.5 49.5 65.8 0 100
FLTA40158 399 38.8 41.8 93.2 47.4 52.6 65.1 0 100
FLTA40219 350 39.2 38.0 85.4 48.9 51.1 65.6 0 100
FLTA40229 330 40.0 38.4 87.6 43.9 56.1 63.8 0 100
FLTA403110 338 31.4 50.0 85.8 50.0 50.0 68.3 100 0
FLTA403811 533 34.9 44.8 83.1 38.6 61.4 65.5 100 0
FLTA403912 522 35.8 46.4 80.8 39.5 60.5 65.8 100 0
FPD4000913 408 33.1 39.2 81.1 48.0 52.0 71.9 100 0
FPD4001013 401 35.9 38.1 83.0 57.6 42.4 75.8 0 100
SAS4002014 432 35.4 45.4 84.5 40.5 59.5 66.8 100 0
SAS4002115 423 36.1 50.3 78.2 37.6 62.4 67.1 100 0
SFCA300216 356 37.1 53.4 84.6 44.1 55.9 62.8 29.8 70.2
SFCA300317 349 38.6 47.6 79.9 43.5 56.5 66.3 0 100
SLGA301018 240 32.6 48.7 80.4 53.7 46.3 68.5 55.4 44.6
SLGA301118 258 33.7 45.7 77.9 47.7 52.3 67.3 48.8 51.2
SLGA500119 254 43.1 45.3 86.6 40.5 59.5 63.4 0 100
SLGA500219 271 40.6 48.0 86.4 41.7 58.3 63.1 0 100
SLGA500320 285 34.7 54.0 88.1 42.1 57.9 63.5 59.6 40.4
SLGA500420 278 34.6 47.8 88.1 46.4 53.6 63.3 48.2 51.8
SLGA500521 277 35.9 50.5 84.8 41.5 58.5 61.5 46.6 53.4
SLGA500621 260 36.6 50.4 87.7 40.8 59.2 61.6 45.0 55.0
SLGA500722 240 40.2 45.8 85.0 42.5 57.5 60.4 53.3 46.7
SLGA500822 234 37.8 45.7 92.3 44.9 55.1 59.6 58.1 41.9
SLGA502223 437 36.3 38.9 84.4 41.6 58.4 61.3 0 100
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produced to graphically present the relationship
between change in overall AQLQ score and change
in percent predicted FEV1 and SFDs. Correlations
were considered mild if r¼ 0.0–0.2, moderate if
r¼ 0.3–0.4, and strong if rX0.5.
Additionally, principal components analyses simi-
lar to that of Juniper32 were performed to explore
associations among the assessments. Varimax rota-
tion was done to group assessments (as factors)
that were most highly correlated such that the
resulting groups of assessments were uncorrelated.
These analyses were conducted on data from
baseline, endpoint, and change from baseline
measurements.
Results
Demographics and baseline characteristics
A total of 8994 patients from 27 clinical trials were
included in this retrospective analysis. Enrollment
in the individual trials ranged from 234 to 533
patients. 1985 subjects were randomized to place-
bo (22.1%) and 7009 subjects were randomized to
active treatment (77.9%). The mean age for the
study population was 36.5 years (7 SD 14.3; range
12–85), with a slightly higher proportion of females
(53.6%) and a large proportion of whites (85.4%).
The mean percent predicted FEV1 was 65.6% (7 SD
10.7; range 25–110). About half of the population
(55.9%) had experienced asthma symptoms for
greater than 15 years and the same proportion of
patients had prior use of inhaled corticosteroids
(55.9%). Background characteristics of the intent-
to-treat populations were comparable among
treatment groups at baseline. Table 2 displays the
overall patient demographics and baseline char-
acteristics of the study sample.
Table 3 displays the baseline values and the mean
change from baseline for the outcomes of interest.
During these studies, percent predicted FEV1 at
baseline was 67.1% (7 SD 12.0; range 18.1–146.2)
with a mean improvement of 7.6% (7 SD 14.0; range
–54.2 to 80.6) by endpoint. At baseline, the mean
percent symptom-free days was 13.1% (7SD 26.4;
range 0–100) with mean improvements of 18.4%
(7SD 38.4; range 100.0 to 100.0) by endpoint. The
mean baseline scores for overall AQLQ scores was
4.5 (7 SD 1.06; range 1.2–7.0). At endpoint, the
mean improvement in overall AQLQ scores was 0.75
(7 SD 1.1; range –4.8 to 5.3).
Correlation analyses
Tables 4 and 5 display the relationship between
HRQL, symptoms, lung function, rescue-free days
and albuterol use at baseline and at change from
baseline.
Baseline correlations
Baseline percent predicted FEV1 was weakly corre-
lated with baseline SFD, RFD, and albuterol use
(r¼ 0.11, 0.17, 0.22, respectively; P o0.001)
(Table 4). In addition, baseline percent predicted
FEV1 was weakly correlated with baseline overall
AQLQ scores (r¼ 0.09; P o0.001). Symptom-free
days (SFD) at baseline was strongly correlated with
baseline RFD (r¼ 0.55, P o0.001). SFD at baseline
was moderately correlated with baseline albuterol
use (r¼0.37, P o0.001). Overall AQLQ scores at
baseline were moderately correlated with SFD,
RFD, and albuterol use at baseline (r¼ 0.36, 0.33,
0.37, respectively; P o0.001).
Change from baseline correlations
Improvements in overall AQLQ scores also corre-
lated moderately with improvements in SFD, RFD,
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Table 2 Demographics and baseline characteris-
tics.
n 8994
Age (yr) 36.5
Male (%) 46.4
White (%) 85.4
Asthma duration (%)
o15 years 44.1
X15 years 55.9
Percent predicted FEV1 67.1
Inhaled steroid use (%)
No 44.1
Yes 55.9
Table 3 Summary of clinical parameters.
Baseline Change
from
baseline
12-weeks
AQLQ overall score 4.5 0.75
Percent symptom-free
days (SFD)
13.1 18.4
Percent predicted FEV1 67.1 7.6
Percent rescue-free days
(RFD)
14.7 24.9
Albuterol use (puffs/
day)
4.5 1.8
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and albuterol use at endpoint (r¼ 0.44, 0.43,
0.49, respectively; P o0.001) (Table 5). At
endpoint, changes in percent predicted FEV1
correlated moderately with changes in overall
AQLQ scores (r¼ 0.38; P o0.001). Improvements
in percent predicted FEV1 were correlated weakly
with changes in SFD, RFD, and albuterol use at
endpoint (r¼ 0.26, 0.27, 0.31, respectively; P
o0.001). A strong correlation was also observed
between SFD at endpoint and RFD at endpoint
(r¼ 0.59; Po0.001). Improvements in percent SFD
at endpoint were moderately correlated with
albuterol use at endpoint (r¼0.40; P o0.001).
Additional analyses were performed with sub-
populations of treated, non-treated (subjects who
received placebo), ICS na.ıve, and ICS experienced
patients (Figs. 1 and 2). These additional analyses
show that the regression analyses comparing HRQL
with lung function and symptoms were consistent
regardless of the type of treatment or ICS use
history.
Partial correlations
There was a moderate partial relationship between
both lung function and HRQL and symptoms and
HRQL at endpoint (r¼ 0.31 and 0.38, respectively;
Po0.001) (Fig. 3). However there was only a mild
partial correlation between lung function and
symptoms at endpoint (r¼ 0.10; Po0.001). Addi-
tional analyses were performed with subpopula-
tions of treated, non-treated (subjects who
received placebo), ICS na.ıve, and ICS experienced
patients. Table 6 shows how these findings were
consistent regardless of the type of treatment and
ICS history.
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Table 4 Relationship between lung function, symptoms, rescue-free days, HRQL and albuterol use at baseline.
Baseline outcomes FEV1 SFD RFD AQLQ Albuterol
FEV1 0.11 0.17 0.09 0.22
SFD 0.11 0.55 0.36 0.37
RFD 0.17 0.55 0.33 0.58
AQLQ 0.09 0.36 0.33 0.37
Albuterol 0.22 0.37 0.58 0.37
SFD¼Percent symptom-free days; RFD¼Percent rescue-free days; FEV1¼Percent predicted FEV1. Albuterol use was measured
as puffs/day.
Table 5 Relationship between change in baseline lung function, symptoms, rescue-free days, HRQL and
albuterol use.
Outcomes change from baseline FEV1 SFD RFD AQLQ Albuterol
FEV1 0.26 0.27 0.38 0.31
SFD 0.26 0.59 0.44 0.40
RFD 0.27 0.59 0.43 0.58
AQLQ 0.38 0.44 0.43 0.49
Albuterol 0.31 0.40 0.58 0.49
SFD¼ Percent symptom-free days; RFD¼ Percent rescue-free days; FEV1 ¼ Percent predicted FEV1. Albuterol use was
measured as puffs/day.
Table 6 Partial correlations in change from baseline relation to treatment.
FEV1 -AQLQ SFD -AQLQ SFD- FEV1
All patients 0.31 0.38 0.10
Treated patients 0.29 0.37 0.09
Not treated patients 0.31 0.38 0.07
ICS na.ıve patients 0.27 0.37 0.11
ICS experienced patients 0.33 0.38 0.10
Lung function was measured via percent-predicted FEV1; HRQL was assessed via overall AQLQ score; and symptoms were
assessed via percent symptom-free days (SFD).
The relationship between lung function and daily symptoms in patients with persistent asthma 1161
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Figure 1 Regression analysis comparing change in health-related quality of life (Overall AQLQ) scores with lung
function (FEV1). Patients were grouped into 5 subgroups. The All group included all patients in the retrospective study.
The non-treated group was composed of patients who received placebo while the treated group was composed of
patients who received active drug in the study. The ICS-na.ıve group was composed of patients who were not taking ICS
at study entry while the ICS dependent were patients who were taking ICS at study entry.
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Figure 2 Regression analysis comparing change health-related quality of life (Overall AQLQ) scores with symptoms
(symptom-free days). Patients were grouped into 5 subgroups. The All group included all patients in the retrospective
study. The non-treated group was composed of patients who received placebo while the treated group was composed of
patients who received active drug in the study. The ICS-na.ıve group was composed of patients who were not taking ICS
at study entry while the ICS dependent were patients who were taking ICS at study entry.
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Principal components analyses
Consistent with the results obtained in Juniper,32
the assessments grouped into four factors for
baseline data. The first factor was composed of
quality of life measurements, i.e., the AQLQ overall
score and each domain score. The second factor
was comprised of airway caliber measurements, in
particular, FEV1 and % predicted FEV1 and morning
and evening PEF. Symptom assessments and rescue
albuterol use were grouped into the third factor.
The fourth factor consisted of nighttime awaken-
ings measurements. This suggests that each group
(factor) represents a distinct component of asthma.
This composition of the factors was similar for
endpoint and change from baseline data.
Discussion
Important objectives of asthma therapy are to
control symptoms and minimize the impact of the
disease on patient functioning.33 From a population
management perspective, both disease manage-
ment (asthma control) and impacts on HRQL are
important issues. Asthma control is dependent on
multiple factors such as medical/drug treatment,
patient adherence, and disease severity. Asthma
control determines patient health outcomes such
as healthcare resource use, functional status and
HRQL. Asthma control serves to assess the need and
evaluate the quality of disease management
programs and assess the response to different
treatment options.
Findings from this retrospective study showed
that HRQL as measured via the AQLQ overall scores
correlated moderately with asthma symptoms
(symptom-free days and rescue-free days) and
albuterol use. Lung function as measured by
changes in percent predicted FEV1 correlated
weakly to moderately with changes in HRQL and
albuterol use while only correlating weakly with
symptoms (symptom-free days and rescue-free
days). Our findings show that even the correlation
from other subjective measures such as symptoms
may at the most be moderate because HRQL is just
one component of symptom outcome and symptoms
are just one of multiple factors affecting patient
HRQL. For instance, in patients experiencing minor
or short term lapses in their asthma control, a
patient’s HRQL may appear unaffected. However,
in cases where the symptoms are extremely
problematic or a lost of asthma control is experi-
enced over a long period of time, a patient’s HRQL
may be highly impacted. Several of the HRQL
parameters, such as activity levels, may not be
greatly affected by changes in pulmonary function
and symptoms. This may be because patients are
learning to live with their disease by avoiding or
omitting from their lifestyle those things that
impact their disease and have the potential to
exacerbate their symptoms. These patients may be
experiencing a small amount of symptoms, none-
theless, the effect of the disease on their HRQL
may be significant due to the changes they have
been forced to make to their lifestyle. This study
suggests that the impact of asthma on a patients’
HRQL is not fully accounted for by objective
measures such as lung function and albuterol use.
There are additional factors that affect a patient’s
HRQL.
The mild correlation between lung function and
symptoms was not surprising. Studies that have
looked at the correlation between measures of
asthma control and asthma severity have found, at
the most, mild correlations. In one study, Charlton
et al.34 lung function, as assessed via peak flow was
found not to be a key management of asthma. The
authors suggested that an asthma-management
plan based on symptoms alone might prove ade-
quate, or even superior, to traditional clinical
measurements.
Published reports of correlations between lung
function and HRQL vary from no effect to moderate
correlations. A hypothesis for the lack of strong
correlation between lung function (FEV1) and HRQL
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Figure 3 Venn diagram showing partial correlation
between lung function, health-related quality of life
and symptoms.
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has been that FEV1 represents a single time point
measurement, whereas HRQL represents an aver-
age over days or weeks.35 This limitation may be
possible to overcome with daily measure of lung
function such as PEF. However, PEF does not
demonstrate a strong correlation with HRQL. Van
der Molen and colleagues36 compared two of the
most frequently used asthma-specific QOL ques-
tionnaires (AQLQ and LWAQ) and two generic HRQL
instruments (SF-36 and PGWB) agonist clinical
objective measures of severity (FEV1, PEF, and
PC20) in order to establish the ability of HRQL
questionnaires to discriminate asthma severity. The
study found that the correlation between HRQL
parameters and objective clinical measures (FEV1,
PEF, and PC20) were low while the correlations
between HRQL parameters and subjective clinical
measures (symptom scores and beta 2-agonist use)
were higher. Subjective measures were found to be
related with each other. Symptom scores and beta
2-agonist use were moderately correlated (r¼ 0.40;
Po0.001). Other studies have only found weak
correlations between symptoms and albuterol
use.37
The findings from this study provide additional
supporting evidence that objective measures only
weakly or at the most moderately correlate with
how patients actually feel and are able to function
on a daily basis. Therefore patient’s HRQL cannot
be assumed or extrapolated from results of clinical
objective measurements alone. Subjective patient
information may be complementary to results from
traditional clinical assessments.
This study suggests that the impact of asthma on
a patients’ HRQL is not fully accounted for by
objective measures such as lung function or
albuterol use. As such, HRQL data complements
rather than duplicates results from traditional,
objective assessments of asthma control. Since a
major goal of asthma therapy is to prevent
symptoms, improve functional status and patients’
sense of well-being, providers should include
routine assessments of HRQL to understand the
patient’s perspective and provide a comprehensive
approach to asthma control.
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